Trial Profile
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacokinetics
- 05 Jan 2012 Additional lead trial centre (Biogen Idec) identified as reported by ClinicalTrials.gov.
- 05 Jan 2012 Company (Biogen Idec) added as trial sponsor/affiliate as reported by ClinicalTrials.gov.
- 05 Jan 2012 Actual patient number (229) added as reported by ClinicalTrials.gov.